World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
34115
World Ranking
9654
National Ranking
4970

James L. Gulley publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where James L. Gulley sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 714 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

James L. Gulley D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where James L. Gulley sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 96 D-Index — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

James L. Gulley is affiliated with the National Institutes of Health in the United States and has a research focus primarily in Medicine, with a specific emphasis on Oncology, Pulmonary and Respiratory Medicine, Immunology, Radiology, Nuclear Medicine and Imaging, and Molecular Biology.

The main topics of their research include Cancer Immunotherapy and Biomarkers, Prostate Cancer Treatment and Research, Immunotherapy and Immune Responses, CAR-T Cell Therapy Research, Cancer Research and Treatments, Prostate Cancer Diagnosis and Treatment, and Radiopharmaceutical Chemistry and Applications.

Gulley's body of work includes contributions to significant recent papers such as:

  • Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce (2020), Journal for ImmunoTherapy of Cancer
  • Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances (2020), Journal for ImmunoTherapy of Cancer
  • Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial (2020), Journal of Thoracic Oncology
  • Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies (2020), Journal for ImmunoTherapy of Cancer
  • Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment (2021), Molecular Oncology

The scientist has collaborated extensively with several coauthors, including:

  • Jeffrey Schlom (107 publications)
  • Ravi A. Madan (76 publications)
  • Renee N. Donahue (74 publications)
  • Fatima Karzai (69 publications)
  • Lisa M. Cordes (65 publications)

James L. Gulley's frequent publication venues demonstrate a focus on clinical oncology and immunotherapy with a significant presence in:

  • Journal of Clinical Oncology (60 publications)
  • Regular and Young Investigator Award Abstracts (39 publications)
  • Journal for ImmunoTherapy of Cancer (38 publications)
  • Annals of Oncology (17 publications)
  • The Oncologist (12 publications)

Best Publications

  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham

  • Androgen Deprivation Therapy for Prostate Cancer

    Nima Sharifi;James L. Gulley;William L. Dahut

  • Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

    Philip W. Kantoff;Thomas J. Schuetz;Brent A. Blumenstein;L. Michael Glode

  • Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

    Andrea B. Apolo;Jeffrey R. Infante;Ani Balmanoukian;Manish R. Patel

  • Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

    Manish R. Patel;John Ellerton;Jeffrey R. Infante;Manish Agrawal

  • Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.

    Benjamin Boyerinas;Caroline Jochems;Massimo Fantini;Christopher R. Heery

  • Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

    William L. Dahut;James L. Gulley;Philip M. Arlen;Yinong Liu

  • Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

    James L. Gulley;Philip M. Arlen;Anne Bastian;Steven Morin

  • Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

    John L. Marshall;James L. Gulley;Philip M. Arlen;Patricia K. Beetham

  • Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.

    Mary L. Disis;Mary L. Disis;Matthew H. Taylor;Karen Kelly;J. Thaddeus Beck

  • Current Landscape of Immunotherapy in Breast Cancer: A Review

    Sylvia Adams;Margaret E. Gatti-Mays;Kevin Kalinsky;Larissa A. Korde

  • Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

    Ravi A Madan;Mahsa Mohebtash;Philip M Arlen;Matteo Vergati

  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

    James L. Gulley;Philip M. Arlen;Ravi A. Madan;Kwong-Yok Tsang

  • A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

    Philip M Arlen;James L Gulley;Catherine Parker;Lisa Skarupa

  • Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.

    James L. Gulley;Arun Rajan;David R. Spigel;Nicholas Iannotti

  • Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

    Julius Strauss;Christopher R. Heery;Jeffrey Schlom;Ravi A. Madan

  • Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

    Christopher R Heery;Geraldine O'Sullivan-Coyne;Ravi A Madan;Lisa Cordes

  • The role of lineage plasticity in prostate cancer therapy resistance

    Himisha Beltran;Andrew Hruszkewycz;Howard I. Scher;Jeffrey Hildesheim

  • Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

    Wilfred D. Stein;James L. Gulley;Jeff Schlom;Ravi A. Madan

  • Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

    James Gulley;Alice P. Chen;William Dahut;Philip M. Arlen

Frequent Co-Authors

Jeffrey Schlom
Jeffrey Schlom National Institutes of Health
Philip M. Arlen
Philip M. Arlen National Institutes of Health
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
William D. Figg
William D. Figg National Institutes of Health
Kwong Y. Tsang
Kwong Y. Tsang National Institutes of Health
James W. Hodge
James W. Hodge National Institutes of Health
Jane B. Trepel
Jane B. Trepel National Institutes of Health
Peter L. Choyke
Peter L. Choyke National Institutes of Health
Baris Turkbey
Baris Turkbey National Institutes of Health
John J. Wright
John J. Wright National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Thinking about alternative or complementary pathways to a traditional medical degree? The healthcare field offers a variety of rewarding online programs that can help you jumpstart your career sooner.

If you're looking for entry into nursing, finding the easiest bsn program to get into can make a difference—especially if you want to avoid highly competitive admissions. In addition, some nursing programs without teas offer a less stressful path by removing standardized test requirements.

Beyond nursing, roles like medical billing and coding are in high demand. Options for financial aid for medical billing and coding can make these programs accessible without breaking the bank.

Those interested in management positions may consider accelerated healthcare programs that let you earn your degree faster and enter the workforce quickly.

With these flexible online degree options, there’s a healthcare career path for every interest and schedule.

Best Scientists Citing James L. Gulley

Trending Scientists

Recently Published Articles